Dew, if one of the worst case scenarios unfolds and MNTA is asked to run a trial comparing its generic Lovenox to the branded one, has it been spelled out how the expenses of such a trial would be split with NVS? Would NVS be responsible for all such costs or would there be a split with MNTA?
Market Data 
Markets 
AI
